Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

NET SPORE Open Trials

Neuroendocrine Tumor Registry 

IRB# 199911057
Participate in registry; allow long term followup; donate blood, tissue for research, including genetics

  • Thomas O'Dorisio, MD

Phase I 131I-MIBG + 177Lu-DOTATATE

IRB# 202005556
Clinical Trails.gov# NCT04614766
Dual target, dual radionuclide; dosimetry-guided therapy with AZEDRA® and Lutathera® in patients with neuroendocrine tumor or pheochromocytoma or paraganglioma

  • David L. Bushnell, MD
  • Kellie Bodeker, PhD

Phase I Intra-arterial 90Y-DOTATOC  

IRB# 201805910
Clinical Trails.gov#  NCT03724409
Dose-escalation trial for treatment of patients with liver metastases

  • Sandeep Laroia, MD
  • Yusuf Menda, MD

68Ga-CXCR4 Biodistribution 

IRB# 201707705
Biodistribution of 68Ga-Pentixafor in patients with typical or atypical lung carcinoid tumors

  • Yusuf Menda, MD
  • David Dick, PhD
  • M. Sue O’Dorisio, MD, PhD

68Ga-CXCR4 Biodistribution 

IRB# 201907794
Biodistribution of 68Ga-Pentixafor in patients with small cell lung carcinoma

  • Yusuf Menda, MD
  • David Dick, PhD
  • M. Sue O’Dorisio, MD, PhD

Dosimetry-guided 177Lu-DOTATATE in children 

IND# 201812772
Clinical Trails.gov#  NCT03923257
Phase I/II trial of 177Lu-DOTATATE (Lutathera®) for children ages six months to 19 years with neuroendocrine tumor, pheochromocytoma, or paraganglioma 

  • M. Sue O’Dorisio, MD, PhD
  • Yusuf Menda, MD

Cabozantinib Versus Placebo in Patients with Neuroendocrine Tumors After Progression on Everolimus

IRB# 201902207
Clinical Trials.gov# 03375320
Randomized, double-blinded Phase III study of Cabozantinib versus placebo in patients with advanced lung or pancreatic neuroendocrine tumors after progression on Everolimus (CABINET)

  • Chandrika Chandrasekharan, MD
  • Joseph Dillon, MD

177Lu-DOTATATE in Grade 2 or 3 Neuroendocrine Tumors

IRB# 202004133
Clinical Trials.gov #03972488

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera® in patients with Grade 2 and Grade 3 advanced gastroentero pancreatic neuroendocrine tumors

  • David Bushnell, MD
  • Kellie Bodeker, PhD
  • Chandra Chandrasekharan, MD